Biomarkers and biologics related with psoriasis and psoriatic arthritis

Int Immunopharmacol. 2023 Sep:122:110646. doi: 10.1016/j.intimp.2023.110646. Epub 2023 Jul 14.

Abstract

Over the past half century, psoriasis is considered as an immune-mediated inflammatory skin disease with the combined hallmarks of autoimmunity and autoinflammation, according to growing volumes of clinical and experimental findings. There is currently no cure for psoriasis, current treatment strategies focus on symptom control, disease minimization, and patient's quality of life enhancement. To meet these challenges, it keeps imperative to discover potential biomarkers, so that not only can they be used for the prediction and monitoring of psoriasis disease in clinic, but also can provide novel therapeutic targets or treatment strategies for psoriasis sufferers. This review systematically demonstrates the research progress of psoriasis-related biomarkers and elaborates their related mechanisms in the pathological development of psoriasis and psoriatic arthritis. In addition, we summarize the development of biologic therapies for psoriasis and psoriatic arthritis in order to drive the broader discussion of psoriasis as an autoimmune-mediated inflammatory skin disease.

Keywords: Autoantibodies; Autoantigens; Biologics; Psoriasis; Psoriatic arthritis.

Publication types

  • Review

MeSH terms

  • Arthritis, Psoriatic* / drug therapy
  • Autoimmune Diseases* / drug therapy
  • Biological Products* / therapeutic use
  • Biomarkers
  • Humans
  • Psoriasis* / drug therapy
  • Quality of Life

Substances

  • Biological Products
  • Biomarkers